Curative treatment for oligometastatic gastroesophageal cancer– results of a prospective multicenter study
(2025) In Langenbeck's Archives of Surgery 410(1).- Abstract
Purpose: Oligometastatic gastroesophageal cancer is a clinical entity with no standard treatment recommendation. Treatment with curative intent has recently emerged as an option for selected patients in contrast to the traditional palliative treatment strategy. This prospective study aimed to assess the safety and efficacy of combined systemic and local treatment with curative intent for patients with oligometastatic gastroesophageal cancer. Methods: In a multicenter study, consecutive patients with gastroesophageal cancer and metastases in the liver and/or extra-regional lymph nodes were screened for inclusion. Eligible patients were offered curatively intended perioperative chemotherapy followed by surgical resection or liver... (More)
Purpose: Oligometastatic gastroesophageal cancer is a clinical entity with no standard treatment recommendation. Treatment with curative intent has recently emerged as an option for selected patients in contrast to the traditional palliative treatment strategy. This prospective study aimed to assess the safety and efficacy of combined systemic and local treatment with curative intent for patients with oligometastatic gastroesophageal cancer. Methods: In a multicenter study, consecutive patients with gastroesophageal cancer and metastases in the liver and/or extra-regional lymph nodes were screened for inclusion. Eligible patients were offered curatively intended perioperative chemotherapy followed by surgical resection or liver ablation. Primary endpoints were treatment safety and feasibility. Secondary outcomes included postoperative mortality, treatment response, progression-free survival, and overall survival. Subgroup analyses were stratified based on oligometastatic location. Results: A total of 29 (82.9%) patients completed treatment with surgical resection (93.1%), liver ablation (3.4%), or definitive chemoradiotherapy (3.4%). Postoperative complications were found in 19 (73.1%) patients, whereas postoperative mortality was 0%. The most common complications included infection (34.6%) and respiratory complications (34.6%). Median overall survival was 20.9 months (interquartile range 11.2–42.6) from diagnosis and 17.0 months (interquartile range 6.4–35.9) from surgery in patients who were treated with neoadjuvant chemotherapy followed by surgery. Median progression-free survival was 5.8 months (interquartile range 3.1–11.3). Conclusion: This study found curative treatment to be a relatively safe option, with an overall survival of 20.8 months and no postoperative mortality.
(Less)
- author
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Esophageal cancer, Gastric cancer, Oligometastatic gastroesophageal cancer, Overall survival, Postoperative complications
- in
- Langenbeck's Archives of Surgery
- volume
- 410
- issue
- 1
- article number
- 10
- publisher
- Springer
- external identifiers
-
- pmid:39680192
- scopus:85212175484
- ISSN
- 1435-2443
- DOI
- 10.1007/s00423-024-03575-7
- language
- English
- LU publication?
- yes
- id
- f89ae7f7-69fc-417f-874c-63a2138f106e
- date added to LUP
- 2025-02-26 13:56:04
- date last changed
- 2025-02-27 03:00:08
@article{f89ae7f7-69fc-417f-874c-63a2138f106e,
abstract = {{<p>Purpose: Oligometastatic gastroesophageal cancer is a clinical entity with no standard treatment recommendation. Treatment with curative intent has recently emerged as an option for selected patients in contrast to the traditional palliative treatment strategy. This prospective study aimed to assess the safety and efficacy of combined systemic and local treatment with curative intent for patients with oligometastatic gastroesophageal cancer. Methods: In a multicenter study, consecutive patients with gastroesophageal cancer and metastases in the liver and/or extra-regional lymph nodes were screened for inclusion. Eligible patients were offered curatively intended perioperative chemotherapy followed by surgical resection or liver ablation. Primary endpoints were treatment safety and feasibility. Secondary outcomes included postoperative mortality, treatment response, progression-free survival, and overall survival. Subgroup analyses were stratified based on oligometastatic location. Results: A total of 29 (82.9%) patients completed treatment with surgical resection (93.1%), liver ablation (3.4%), or definitive chemoradiotherapy (3.4%). Postoperative complications were found in 19 (73.1%) patients, whereas postoperative mortality was 0%. The most common complications included infection (34.6%) and respiratory complications (34.6%). Median overall survival was 20.9 months (interquartile range 11.2–42.6) from diagnosis and 17.0 months (interquartile range 6.4–35.9) from surgery in patients who were treated with neoadjuvant chemotherapy followed by surgery. Median progression-free survival was 5.8 months (interquartile range 3.1–11.3). Conclusion: This study found curative treatment to be a relatively safe option, with an overall survival of 20.8 months and no postoperative mortality.</p>}},
author = {{Norén, N. and Rouvelas, I. and Lundell, L. and Nilsson, M. and Sunde, B. and Szabo, E. and Edholm, D. and Hedberg, J. and Smedh, U. and Hermansson, M. and Lindblad, M. and Klevebro, F.}},
issn = {{1435-2443}},
keywords = {{Esophageal cancer; Gastric cancer; Oligometastatic gastroesophageal cancer; Overall survival; Postoperative complications}},
language = {{eng}},
number = {{1}},
publisher = {{Springer}},
series = {{Langenbeck's Archives of Surgery}},
title = {{Curative treatment for oligometastatic gastroesophageal cancer– results of a prospective multicenter study}},
url = {{http://dx.doi.org/10.1007/s00423-024-03575-7}},
doi = {{10.1007/s00423-024-03575-7}},
volume = {{410}},
year = {{2025}},
}